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Abstract
Background: Increasing our understanding of the factors affecting the severity of the 2009 A/H1N1 influenza pandemic
in different regions of the world could lead to improved clinical practice and mitigation strategies for future influenza
pandemics. Even though a number of studies have shed light into the risk factors associated with severe outcomes of
2009 A/H1N1 influenza infections in different populations (e.g., [1-5]), analyses of the determinants of mortality risk
spanning multiple pandemic waves and geographic regions are scarce. Between-country differences in the mortality
burden of the 2009 pandemic could be linked to differences in influenza case management, underlying population
health, or intrinsic differences in disease transmission [6]. Additional studies elucidating the determinants of disease
severity globally are warranted to guide prevention efforts in future influenza pandemics.
In Mexico, the 2009 A/H1N1 influenza pandemic was characterized by a three-wave pattern occurring in the spring,
summer, and fall of 2009 with substantial geographical heterogeneity [7]. A recent study suggests that Mexico
experienced high excess mortality burden during the 2009 A/H1N1 influenza pandemic relative to other countries [6].
However, an assessment of potential factors that contributed to the relatively high pandemic death toll in Mexico are
lacking. Here, we fill this gap by analyzing a large series of laboratory-confirmed A/H1N1 influenza cases, hospitalizations,
and deaths monitored by the Mexican Social Security medical system during April 1 through December 31, 2009 in
Mexico. In particular, we quantify the association between disease severity, hospital admission delays, and
neuraminidase inhibitor use by demographic characteristics, pandemic wave, and geographic regions of Mexico.
Methods: We analyzed a large series of laboratory-confirmed pandemic A/H1N1 influenza cases from a prospective
surveillance system maintained by the Mexican Social Security system, April-December 2009. We considered a spectrum
of disease severity encompassing outpatient visits, hospitalizations, and deaths, and recorded demographic and
geographic information on individual patients. We assessed the impact of neuraminidase inhibitor treatment and
hospital admission delay (≤ > 2 days after disease onset) on the risk of death by multivariate logistic regression.
Results: Approximately 50% of all A/H1N1-positive patients received antiviral medication during the Spring and
Summer 2009 pandemic waves in Mexico while only 9% of A/H1N1 cases received antiviral medications during the fall
wave (P< 0.0001). After adjustment for age, gender, and geography, antiviral treatment significantly reduced the risk of
death (OR= 0.52 (95% CI: 0.30, 0.90)) while longer hospital admission delays increased the risk of death by 2.8-fold (95%
CI: 2.25, 3.41).
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Conclusions: Our findings underscore the potential impact of decreasing admission delays and increasing antiviral
use to mitigate the mortality burden of future influenza pandemics.
Keywords: 2009 A/H1N1 influenza pandemic, Neuraminidase inhibitors, Antivirals, Case fatality ratio, Multivariate
logistic regression, Hospital admission delay, Pandemic wave, Mexico.
Background
Increasing our understanding of the factors affecting the
severity of the 2009 A/H1N1 influenza pandemic in dif-
ferent regions of the world could lead to improved clin-
ical practice and mitigation strategies for future
influenza pandemics. Even though a number of studies
have shed light into the risk factors associated with se-
vere outcomes of 2009 A/H1N1 influenza infections in
different populations (e.g., [1-5]), analyses of the case fa-
tality ratio, e.g. the proportion of deaths among all
symptomatic infections, spanning multiple pandemic
waves, and geographic regions are scarce. Between-
country differences in the mortality burden of the 2009
pandemic [6] could be linked to differences in influenza
case management, underlying population health, or in-
trinsic differences in disease transmission. Additional
studies elucidating the determinants of disease severity
globally are warranted to guide prevention efforts in fu-
ture influenza pandemics.
In Mexico, the 2009 A/H1N1 influenza pandemic was
characterized by a three-wave pattern occurring in the
spring, summer, and fall of 2009 with substantial geo-
graphical heterogeneity [7]. A recent study suggests that
Mexico experienced high excess mortality burden during
the 2009 A/H1N1 influenza pandemic relative to other
countries [6]. However, an assessment of potential fac-
tors that contributed to the relatively high pandemic
death toll in Mexico are lacking. Here, we fill this gap by
analyzing a large series of laboratory-confirmed A/H1N1
influenza cases, hospitalization, and deaths monitored by
the Mexican Social Security medical system during April
1 through December 31, 2009 in Mexico. In particular,
we quantify the association between disease severity,
hospital admission delays, and neuraminidase inhibitor
use by demographic information, pandemic wave, and
geographic regions of Mexico.
Methods
Epidemiological data
We used patient level data collected by a prospective epi-
demiological surveillance system put in place specifically
for the 2009 influenza pandemic by the Mexican Insti-
tute for Social Security (IMSS) [7,8]. IMSS is a tripartite
Mexican health system covering approximately 40% of
the Mexican population comprising workers in the pri-
vate sector and their families, relying on a network of
1,099 primary health-care units and 259 hospitals nation-
wide. The age and gender distributions of the population
affiliated with IMSS are representative of the general
Mexican population [7].
We obtained information on all patients attending any
primary-care clinic or hospital with influenza-like-illness
(ILI) reported across 32 Mexican states between April 1
and December 31, 2009. Patient-level information was
entered into a standardized online form by hospital or
clinic epidemiologists during the pandemic; a single record
was obtained for each patient, ensuring that each patient is
counted only once. ILI was defined as a combination of
cough, headache, fever, and one or more of the following
symptoms: sore throat, rhinorrhoea, arthralgias, myalgia,
prostration, thoracic pain, abdominal pain, nasal conges-
tion, diarrhea. For persons> 65 years presence of fever
was not required [8], while for infants, irritability was
included in the list of associated symptoms.
Respiratory swabs were obtained from ILI patients for
influenza testing [7]; rRT-PCR was performed to identify
influenza A/H1N1 [9] by the Instituto de Diagnóstico y
Referencia Epidemiológica (InDRE) until May 25, 2009,
after which point samples were analyzed by La Raza, an
IMSS auxiliary laboratory to InDRE. The proportion of
ILI patients tested for influenza increased rapidly during
the first 2–3 weeks of the pandemic, at which point test-
ing rates remained stable at ~33% throughout the pan-
demic, across geographic regions, and age groups [7].
For each ILI patient, we compiled demographic informa-
tion (age in yrs, and gender), pandemic A/H1N1 status
(positive, negative; for those tested), disease severity (out-
patient, inpatient, and death), reporting state (including 31
states plus the Federal District), dates of onset of symp-
toms (self-reported) and hospital admission and discharge
(if hospitalized), and whether the patient was treated with
neuraminidase inhibitors upon initial consultation or at
hospital admission. Hospitalized patients had to be admit-
ted with acute respiratory infection (ARI), defined as re-
spiratory difficulty with fever and cough, combined with
one or more of the following clinical symptoms: confine-
ment to bed, thoracic pain, polypnea, or acute respiratory
distress syndrome. Children <5 years with pneumonia or
severe pneumonia that required hospitalization were also
considered as ARI cases.
In Mexico, antiviral treatment with neuraminidase
inhibitors (Oseltamivir and Zanamivir) was considered
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for all ILI cases upon initial clinical evaluation and indi-
vidual risk of developing complications [10]. Specifically,
antiviral treatment was recommended for all cases pre-
senting with severe symptoms, irrespective of age or
underlying conditions. For cases presenting mild symp-
toms, antiviral treatment was recommended for high-risk
patients only, which included infants <5 y, seniors >65
y, persons with lung disease (including asthma), cardio-
vascular disease (except for systemic arterial hyperten-
sion), renal disease, hematologic disease, neurologic
disease, neuromuscular or metabolic disorders (including
diabetes), and immune deficiency disease. Records with
missing data were excluded from the analysis; less than
5% of records had one or more missing variables.
We defined the admission delay as the time elapsed
from symptoms onset to hospitalization admission, and
hospital length of stay was defined as the number of days
from hospital admission to discharge or death. Given
that recommendations for neuraminidase inhibitors
stipulate that treatment should be provided within 48 h
of disease onset, we stratified admission delay into two
groups: <=2 and >2 days and assessed the association
between admission delay, antiviral treatment, and dis-
ease severity. To evaluate potential differences in disease
severity over time and between regions, we considered
three temporally-distinct pandemic waves in the spring
(April 1 to May 20), summer (May 21 to August 1) and fall
(August 2 to December 31) of 2009 as in past work [7].
The spring pandemic wave was mainly confined to the
greater Mexico City area and other central states; the sum-
mer wave focused on southeastern states; and the third
wave was associated with widespread influenza activity.
Case fatality ratios
The case fatality ratio (CFR) measures the proportion of
deaths from all symptomatic infections, e..g, the prob-
ability that an infection causes death, and can be used as
a measure of disease severity. Here we estimated the case
fatality ratio among ILI cases, namely the proportion of
ILI deaths among all ILI cases, which potentially includes
the contribution of non-influenza pathogens (CFRili = ILI
deaths/ILI cases). We also estimated the case fatality
ratio among laboratory-confirmed A/H1N1 influenza
outpatients and inpatients (CFRflu =A/H1N1 deaths/A/
H1N1 cases), and the case fatality ratio among labora-
tory-confirmed A/H1N1 hospitalizations (CFRh =A/
H1N1 inpatient deaths/A/H1N1 inpatient cases). Next,
we analyzed the case fatality ratio according to neur-
aminidase inhibitor use, admission delay, age groups,
pandemic waves, and geographic regions.
Multivariate regression analysis
We used multivariate logistic regression to evaluate the
risk of death among A/H1N1 inpatients after adjusting
for age, gender, pandemic wave, geographic region, ad-
mission delay (<=2 days vs. >2 days), and antiviral treat-
ment. The interaction between antiviral treatment and
admission delay was also quantified due to the fact that
patients admitted earlier in their disease course had a
higher probability of receiving antiviral treatment. The
effects of model predictors were measured using odds
ratios (95% CI) and P values. Records with missing data
(e.g., admission delay, antiviral use) were excluded from
the analysis.
Statistical analyses were performed using PASW Statis-
tics 18.0 and Matlab (The Mathworks, Inc).
Ethics Committee approval was not necessary accord-
ing to local regulations. All the data were de-identified.
Data employed in this study are routinely collected for
epidemiological surveillance purposes.
Results
Temporal pandemic profile, admission delays, and length
of hospital stay
The characteristics of laboratory-confirmed A/H1N1 in-
fluenza cases by pandemic wave are shown in Table 1,
and the temporal profile of outpatients, hospitalizations,
and deaths in the IMSS database is illustrated in Figure 1.
Overall, there were 117,818 ILI cases reported to the
IMSS system between April and December 2009. The
total number of laboratory-confirmed A/H1N1 cases
(hospitalizations) reported in the spring, summer, and
fall waves were 615 (159), 5,741 (371), and 21,081
(3,461), respectively. A similar proportion of females and
males were affected during each of the three pandemic
waves (Chi-square test, P = 0.91, Table 1).
The average admission delay among laboratory-
confirmed A/H1N1 inpatients was 3.1 days (95% CI: 3.0,
3.2). About half of the A/H1N1 inpatients in the spring
wave were admitted within 2 days of symptoms onset
(Table 2). The admission delay was longer on average
during the spring than the summer and fall (4.2 d vs. 3.1
d, Wilcoxon test, P = 0.006) and lower in the southeast-
ern region than in the rest of Mexico (2.5 d vs. 3.2 d,
Chi-square test, P< 0.0001). The fraction of deaths
among A/H1N1 inpatients was ~3-fold higher among
those with admission delays >2 days compared to A/
H1N1 inpatients with admission delays<=2 days (Chi-
square test, P< 0.0001). Moreover, A/H1N1 inpatients
who died in the hospital experienced longer admission
delay than those who recovered (4.8 (95% CI: 4.4, 5.1) vs
2.8 days (95% CI: 2.7, 3.0), Wilcoxon test, P< 0.0001).
The average admission delay was significantly shorter
among persons <50 y (3.0 days (95% CI: 2.9, 3.1)) than
in older individuals (3.7 days (95% CI: 3.4, 4.1)).
The average length of hospital stay among A/H1N1
inpatients was 5.3 days (95% CI: 5.1, 5.6) and did not
change over time (P = 0.07). However, length of stay was
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significantly shorter among A/H1N1 inpatients with ad-
mission delays<=2 days (4.2 days (95% CI: 3.9, 4.4))
compared to inpatients with admission delays >2 days
(5.9 days (95% CI: 5.5, 6.3), Wilcoxon test, P< 0.0001).
Temporal and regional patterns of neuraminidase
inhibitor administration
A total of 19,807 (16.8%) of ILI patients were treated
with antivirals, with higher treatment proportion among
laboratory-confirmed H1N1 patients overall (19.3% in A/
H1N1-positive cases vs. 12.5% of A/H1N1-negative
cases, Chi-square test, P< 0.0001). There was higher
antiviral use in the outpatient than in the inpatient set-
ting (20.1% vs. 14.1%, P< 0.0001, Table 3). Among A/
H1N1 inpatients, antivirals were administered more fre-
quently to patients with short admission delay (15.4% for
delay< 2 dys vs. 12.7% for delays>= 2 days, Chi-square
test, P = 0.021), with no difference between the spring
and summer waves (P> 0.16).
There was a marked shift in patterns of antiviral ad-
ministration at IMSS facilities by the fall of 2009. While
antiviral administration remained high at 50% among
H1N1-confirmed cases throughout the spring and sum-
mer pandemic waves (April-July, 2009) with peak use at
~70% in June, antiviral used declined significantly later
in the pandemic to ~9% (Figure 2A-B and Table 3, Chi-
square test, P< 0.0001). Southeastern states had 2.6-3.3
fold higher proportion of A/H1N1 influenza cases trea-
ted with neuraminidase inhibitors compared to other
regions (Table 3).
Table 1 Characteristics of laboratory-confirmed A/H1N1
influenza cases by pandemic wave, Mexico, 01 April
through 31 December, 2009
Variable Pandemic wave
Wave 1 Wave 2 Wave 3 P valuea
Geographic
Central 433/615
(70.4)
602/5741
(10.5)
9948/21081
(47.2)
<0.0001
Southern 58/615
(9.4)
3734/5741
(65)
2322/21081
(11)
Other states 124/615
(20.2)
1405/5741
(24.5)
8811/21081
(41.8)
Demography Female 310/612
(50.4)
2922/5690
(51)
10780/21173
(51.2)
0.91
Age (years)
<18 277/611
(45)
3020/5688
(53)
10187/21167
(48)
<0.0001
18–49 283/611
(46)
2410/5688
(42)
9416/21167
(44)
>50 51/611
(8)
258/5688
(5)
1564/21167
(7)
Patients according to severity
Outpatients 456/615
(74.2)
5370/5741
(93.5)
17620/21081
(83.6)
<0.0001
Hospitalizations 131/615
(21.3)
330/5741
(5.7)
2944/21081
(14.0)
Deaths 28/615
(4.6)
41/5741
(0.7)
517/21081
(2.4)
Wave 1 (spring) refers to April 1 through May 20; wave 2(summer) refers to
May 21 through August 1; wave 3 (fall) refers to August 2 through December
31 of 2009. Data are percentages of cases unless otherwise specified.
a Determined by the Chi-square test statistic.
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Figure 1 Weekly number of new laboratory-confirmed A/H1N1 influenza outpatients, inpatients, and deaths by date of symptoms
onset from April 1 to December 31, 2009 in Mexico.
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No difference by gender in antiviral administration was
observed among laboratory-confirmed A/H1N1 outpati-
ents and inpatients (P = 0.38). Antiviral use was slightly
lower among patients aged 50 years of age and older
than among younger patients (Table 3, Chi-square test, P
< 0.0001). Antiviral use declined with severity of disease,
with treatment percentage of 20.1% among A/H1N1-
positive outpatients, 14.6% among A/H1N1-positive
inpatients, and 11.1% of A/H1N1-positive decedents
(Chi-square test, P< 0.0001). Temporal trends of anti-
viral use were consistent by severity status, geographic
region, gender, and age groups, and revealed consistently
lower usage during the fall pandemic wave (Figure 2B,
Table 3).
Case fatality ratios
We found significant temporal and geographic differences
in the influenza-related case fatality ratios (Figure 2C).
The overall CFR was estimated at 2.1% (2.0, 2.3) based on
laboratory-confirmed A/H1N1 cases and 1.2% (1.1,1.2)
based on ILI cases. CFR estimates were significantly lower
during the period of high antiviral use (April-July,
CFRflu= 1.1%, CFRili = 0.9%) than during the period of
low antiviral use in the fall (August-December, CFRflu=
2.4%, CFRili = 1.2%, Chi-square test, P< 0.0001, Table 4).
This difference was even more pronounced after exclusion
of the month of April associated with unusually long ad-
mission delays (May-July, CFRflu= 0.8%, CFRili = 0.6%,
Chi-square tests, P< 0.0001).
Case-based CFR increased with older age, consistently
across pandemic waves (Table 4). The CFR was lowest in
the southeastern region, which also had the highest rates
of antiviral administration and highest A/H1N1 influenza
activity in summer (Table 3). Yet, the southeastern re-
gion also experienced a significantly lower CFRflu than
other regions later in the pandemic, as antiviral use had
decreased (1.16% vs. 2.61%, Chi-square test, P< 0.0001).
We also estimated the hospital-based CFR, CFRh, at
14.4% (13.3, 15.6). CFRh increased significantly with ad-
mission delay independently of geographic region, gen-
der, and age groups (Table 5). The overall CFRh was
about 3-fold higher for inpatients with admission delays
>2 days than for those inpatients with admission delays
<=2 days (Table 5). Consistent with geographical pat-
terns in case-based CFR, CFRh was significantly lower in
the southeastern region than in other regions (Table 5).
We found a consistent relationship between disease
severity and antiviral use. Specifically, CFR was lower
among treated than untreated patients if considering all
confirmed A/H1N1 cases (1.2% vs. 2.3%, Chi-square test,
P< 0.0001), all ILI cases (CFR= 0.8% vs. 1.2%, Chi-
square test, P< 0.0001), or A/H1N1-positive inpatients
alone (11.6% vs. 15.2%, Chi-square test, P = 0.03).
Multivariate regression analysis
Antiviral treatment and hospital admission delays were
significantly associated with the risk of death among A/
H1N1 inpatients after adjusting for age, gender, geo-
graphic region, and pandemic wave in a multivariate lo-
gistic regression model with backward elimination.
Antiviral treatment significantly reduced the risk of
death (OR= 0.52 (95% CI: 0.30, 0.90)) while admission
delays >2 days increased the risk of death by 2.8-fold
(95% CI: 2.25, 3.41) among A/H1N1 inpatients. We
included an interaction term between antiviral treatment
and admission delay, which was statistically significant
(OR= 2.0 (95% CI: 1.03, 3.85)), suggesting that the pro-
tective effect of treatment was negated among patients
experiencing long admission delays. For the group of A/
H1N1 inpatients with admission delays<=2 days, anti-
viral treatment significantly reduced the risk of death
(OR= 0.53 (95% CI: 0.30, 0.94)) whereas for the group of
A/H1N1 inpatients with admission delays >2 days, anti-
viral treatment did not significantly reduce the risk of
death (OR= 0.96 (95% CI: 0.65, 1.43)).
Male inpatients experienced an increased risk of influ-
enza-related death (OR= 1.46 (95% CI: 1.21, 1.77))
Table 2 Characteristics of laboratory-confirmed A/H1N1
influenza inpatients according to admission delay,
Mexico, 01 April through 31 December, 2009
Variable Time from symptoms
onset to admission
P valuea
Days from
symptoms
onset to admission
Group
1< =2 days
Group
2> 2 days
No. of patients
(% of all study
inpatients)
2223 (58%) 1610 (42%) P< 0.0001
Disease outcome
Deaths, No. (%) 177(8%) 375 (23.3%) P< 0.0001
Pandemic wave
Spring wave 73 (50.3%) 72 (49.7%) P = 0.085
Summer wave 223 (61.1%) 142 (38.9%)
Fall wave 1927 (58.0%) 1396 (42.0%)
Gender
Females, No. (%) 1293 (58.2%) 889 (55.2%) P = 0.07
Age group (y), No. (% in each group)
< 18 800 (65.4%) 424 (34.6%) P< 0.0001
18–49 1114 (56.5%) 857 (43.5%)
>50 307 (48.3%) 328 (51.7%)
Antiviral treatment, No. (%)
Spring wave 31 (44.3%) 39 (55.7%) P = 0.003
Summer wave 114 (64.4%) 63 (35.6%)
Fall wave 197 (65.7%) 103 (34.3%)
a Chi-square test.
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compared to females. Moreover, the southeastern region
experienced a significant reduced risk of death compared
to other regions (OR= 0.50 (95% CI: 0.35, 0.68)). The
pandemic wave indicator was the only predictor that was
eliminated from the model by the backward elimination
procedure (P = 0.53).
Discussion
We have carried out a detailed analysis of the association
between case fatality ratio, admission delays, and neur-
aminidase inhibitor administration patterns in ILI and la-
boratory-confirmed pandemic influenza A/H1N1 patients.
Our data are based on individual-level patient information
collected through a prospective influenza surveillance sys-
tem during Apr-Dec 2009 in Mexico. In our large sample
comprising 117,818 patients, the risk of death among A/
H1N1 inpatients was significantly associated with admis-
sion delay and antiviral treatment, in line with previous
studies [2,11-17]. We also found that age, gender, and
geography were significantly associated with risk of death.
Our findings suggest significant antiviral effectiveness
when administered during the early symptomatic phase
(<=2 days) when antiviral treatment is considered clinic-
ally meaningful [18-21]. Our results also confirm an in-
creasing case fatality ratio with older age [7,22,23]. Finally,
our results reveal marked temporal trends in patterns of
antiviral use in Mexico, dropping to ~9% by fall 2009
from 50% in earlier pandemic months.
We found the case fatality ratio based on laboratory-
confirmed A/H1N1 influenza cases (outpatients and
inpatients) to be 2- to 3-fold lower during the period of
high antiviral administration during April-July, 2009
compared to the period of low antiviral administration
(August-December, 2009). Accordingly, CFR was 1.5 to
1.9 times lower among ILI and A/H1N1 patients treated
with antivirals compared to untreated patients [2,14]. For
A/H1N1-positive inpatients with admission delay<=2
days, CFR was twice lower for the treated group than
the untreated group, which is in agreement with previous
studies [15-17].
We did not find any difference in length of hospital
stay by antiviral treatment status. A recent study found
that antiviral treatment reduced the length of stay by
18% for hospitalized children with seasonal influenza
[21]. No pandemic study is available for comparison with
our data.
We did not find evidence of temporal trends in sever-
ity of pandemic infections beyond those associated with
antiviral use and hospital admission delay, as suggested
by the lack of significance of the pandemic wave indica-
tor in our multivariate model. This suggests that there
was no meaningful change in severity of circulating
Table 3 Rates of antiviral administration (mean and 95% confidence intervals) among laboratory-confirmed A/H1N1
influenza cases by pandemic wave, Mexico, 01 April through 31 December, 2009
Variable Total A/H1N1
cases
Pandemic wave P valuea
Wave 1 Wave 2 Wave 3
No. patients that received antivirals
(% of total A/H1N1 cases)
19.3% (18.8, 19.7) 48.6% (44.6,52.6) 54.9% (53.6,56.2) 8.7% (8.32,9.09) P< 0.0001
Geographic
Central 12.1% (11.5,12.7) 41.6% (36.9,46.4) 38.5% (34.6,42.6) 9.19% (8.63,9.78) P< 0.0001
Southern 39.1% (37.9,40.4) 65.5% (51.9,77.5) 59.8% (58.3,61.4) 5.13% (4.27,6.11) P< 0.0001
Other states 15.2% (14.5,15.9) 65.3% (56.3,73.6) 48.8% (46.2,51.5) 9.08% (8.48,9.7) P< 0.0001
Demography
Female 19.4% (18.8,20.1) 47.7% (42.1,53.5) 53.8% (52,55.6) 9.33% (8.79,9.9) P< 0.0001
Male 19% (18.4,19.7) 49.5% (43.8,55.3) 56.1% (54.2,57.9) 8.03% (7.51,8.57) P< 0.0001
Age (years)
<18 19.5% (18.9,20.2) 50.2% (44.2,56.2) 58.2% (56.5,60) 7.09% (6.59,7.6) P< 0.0001
18–49 19.8% (19.1,20.5) 48.2% (42.3,54.2) 52.4% (50.4,54.4) 10.4% (9.79,11) P< 0.0001
>50 14.2% (12.7,15.9) 43.1% (29.3,57.8) 40% (34,46.2) 8.99% (7.61,10.5) P< 0.0001
Patients according to severity
Outpatients 20.1% (19.6,20.7) 48.7% (44,53.4) 55.4% (54,56.7) 8.67% (8.25,9.09) P< 0.0001
Inpatients 14.6% (13.4,15.8) 46.6% (37.8,55.5) 49.4% (43.9,54.9) 9.29% (8.26,10.4) P< 0.0001
Deaths 11.1% (8.68,13.9) 57.1% (37.2,75.5) 39% (24.2,55.5) 6.4% (4.44,8.86) P< 0.0001
Wave 1 (spring) refers to April 1 through May 20; wave 2 (summer) refers to May 21 through August 1; wave 3 (fall) refers to August 2 through December 31 of 2009.
a Determined by the Chi-square test statistic.
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pandemic influenza viruses throughout 2009 in Mexico,
and resistance to antivirals was not an issue. This is in
line with an analysis of the risk of death among hospita-
lized cases during the summer and fall 2009 A/H1N1
pandemic waves in England [24].
Hospital admission delay was the strongest predictor
of death among laboratory-confirmed A/H1N1 influenza
inpatients, followed by antiviral treatment, in a multivari-
ate model adjusting for age, gender, and geographic re-
gion. Admission delays <2 days significantly decreased
risk of death by 55-71% while antiviral treatment
reduced risk of death by ~48%, consistent with previous
studies [2,4,11-17,25-28].
Our multivariate logistic regression analysis also sup-
ported a ~46% (95% CI 21-77%) increased mortality risk
of death among A/H1N1 male inpatients compared to
females. One study has reported a higher risk of
hospitalization among males with pandemic A/H1N1
influenza in South Korea [29]. Our results also
indicated that the southeastern region experienced a
reduced risk of A/H1N1 inpatient death after control-
ling for antiviral use and other factors. We do not ex-
pect that socio-economic or ethnic differences played a
role given that all patients covered through the IMSS
health system in Mexico are workers and their families.
Overall this suggests that factors beyond admission
delays and antiviral treatment could have played a role
in the severity of the 2009 A/H1N1 influenza pandemic,
including behavioral factors and case management prac-
tices. We were not able to ascertain whether the avail-
ability of critical case management and intensive care
units differed by geographical area or over time.
The most intriguing finding of our study was perhaps
the sharp drop in antiviral use from 50% in the spring
and summer wave to 9% in the main fall pandemic in
Mexico. Antiviral use was similar among inpatients and
outpatients in the fall, suggesting that decision to treat
was not related to symptoms severity. This pronounced
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Figure 2 Temporal evolution of neuraminidase inhibitor administration rates and the case fatality ratio by date of symptoms onset
during the 2009 A/H1N1 influenza pandemic in Mexico, AprilDecember 2009. A) Monthly number of new laboratory-confirmed A/H1N1
influenza outpatients and inpatients, B) Monthly percentage of laboratory-confirmed A/H1N1 influenza outpatients and A/H1N1 inpatients that
received antiviral medications during the pandemic period, and C) the monthly case fatality ratio (and corresponding 95% CIs) based on all A/
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change in clinical practice could be explained in part by
the great uncertainty surrounding pandemic severity in
the early pandemic stages, with early data suggesting
atypically severe disease [30,31]. By the end of the sum-
mer 2009 pandemic wave, it became clear that the
severity of the 2009 pandemic virus was comparable to
that of contemporaneous seasonal influenza epidemics
[32]. Accordingly, antivirals were administered much
more conservatively although antiviral availability was
not an issue at IMSS facilities. Overall, our findings
Table 5 Case fatality ratios (mean and 95% CIs) among laboratory-confirmed A/H1N1 inpatients according to
admission delay, Mexico, 01 April through 31 December, 2009
Variable Overall case
fatality ratio
Admission delay P valuea
<=2 days >2 days
Total A/H1N1 deaths
(% of total A/H1N1 cases)
14.4% (13.3,15.6) 8.0% (6.9,9.17) 23.3% (21.2,25.4) P< 0.0001
Geographic
Central 14.9% (13.3,16.6) 7.9% (6.37,9.7) 23.9% (21,26.9) P< 0.0001
Southern 7.2% (5.3,9.6) 4.0% (2.3,6.4) 13.5% (9.14,18.9) P< 0.0001
Other states 16.9% (14.9,19) 10.1% (8.0,12.4) 26% (22.5,29.7) P< 0.0001
Pandemic wave
Spring 15.9% (10.3,22.8) 5.5% (1.5,13.4) 26.4% (16.7,38.1) P = 0.001
Summer 10.4% (7.47,14) 5.8% (3.1,9.8) 17.6% (11.7,24.9) P< 0.0001
Fall 14.8% (13.6,16) 8.3% (7.1,9.6) 23.7% (21.5,26) P< 0.0001
Demography
Female 12.5% (11.2,14) 7.4% (6.1,9.0) 19.9% (17.3,22.7) P< 0.0001
Male 16.9% (15.1,18.8) 8.7% (7.0,10.7) 27.5% (24.2,30.9) P< 0.0001
Age (years)
<18 6.3% (5,7.8) 3.4% (2.2,4.9) 11.8% (8.9,15.3) P< 0.0001
18–49 16.6% (15,18.4) 8.4% (6.9,10.2) 27.3% (24.3,30.4) P< 0.0001
>50 23% (19.8,26.5) 17.9% (13.8,22.7) 27.7% (23,32.9) P = 0.003
a Determined by the linear Chi-square test statistic.
Table 4 Case fatality ratios (mean and 95% CIs) among laboratory-confirmed A/H1N1 influenza cases by pandemic
wave, Mexico, 01 April through 31 December, 2009
Variable Overall case
fatality ratio
Pandemic wave P valuea
Wave 1 Wave 2 Wave 3
Total A/H1N1 deaths
(% of total A/H1N1 cases)
2.1% (2.0,2.3) 4.6% (3.1,6.5) 0.7% (0.5,1.0) 2.5% (2.3,2.7) P< 0.0001
Geographic
Central 2.7% (2.4,3.0) 5.5% (3.6,8.1) 1.7% (0.8,3.0) 2.7% (2.4,3.0) P< 0.0001
Southern 0.8% (0.6,1.0) 0% (0,6.2) 0.5% (0.3,0.8) 1.2% (0.8,1.7) P< 0.0001
Other states 2.3% (2.1,2.6) 3.2% (0.9,8.1) 0.9% (0.4,1.5) 2.6% (2.2,2.9) P< 0.0001
Demography
Female 2.1% (1.8,2.3) 4.5% (2.5,7.5) 0.6% (0.3,0.9) 2.4% (2.1,2.7) P< 0.0001
Male 2.2% (2.0,2.5) 4.6% (2.5,7.6) 0.9% (0.6,1.3) 2.5% (2.2,2.8) P< 0.0001
Age (years)
<18 0.6% (0.5,0.8) 0.7% (0.1,2.6) 0.1% (0.04,0.3) 0.8% (0.6,0.97) P< 0.0001
18–49 2.8% (2.5,3.1) 6.0% (3.5,9.4) 1.2% (0.8,1.7) 3.2% (2.8,3.6) P< 0.0001
>50 8.5% (7.2,9.8) 15.7% (7.0,28.6) 3.5% (1.6,6.5) 9.1% (7.7,10.6) P< 0.0001
Wave 1 (spring) refers to April 1 through May 20; wave 2 (summer) refers to May 21 through August 1; wave 3 (fall) refers to August 2 through December 31 of 2009.
a Determined by the Chi-square test statistic.
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suggest that higher rates of timely antiviral treatment
during the 2009 fall pandemic wave in Mexico could
have led to a substantially lower death toll. As the novel
pandemic A/H1N1 virus continues to circulate around
the world, antiviral treatment should be considered for
the great majority of severe ILI patients requiring
hospitalization.
Case fatality ratio estimates for the 2009 A/H1N1 in-
fluenza pandemic have differed by one to two orders of
magnitude between countries [33-40]. Our case-based
severity estimates for Mexico are relatively high at 2%
for A/H1N1-positive cases and 14% for hospitalized A/
H1N1-positive patients. These high estimates likely re-
flect a bias of the Mexican IMSS influenza surveillance
system towards the higher levels of the severity pyramid
due to difficulties in identifying asymptomatic or mild
cases [35]. In general it is difficult to compare CFR esti-
mates between countries due to differences in patient
care and probability of seeking care. However, estimates
of case fatality ratio are useful comparative measures of
severity across regions of the same country, pandemic
waves, age groups, and patterns of neuraminidase inhibi-
tor administration.
Lower CFR estimates in other countries could reflect
in part higher rates of neuraminidase inhibitor treatment
and prophylaxis, compared to those in Mexico [41-44].
In the US, rates of antiviral treatment among hospita-
lized A/H1N1 patients remained high throughout the
pandemic at 50-82% [4,45,46]. In contrast, the distribu-
tion of admission delays in our study is generally similar
to that in other studies [13,44,47,48]. One study reported
a short median admission delay of one day in emergency
departments, antiviral treatment rates >99%, and no
pandemic-associated death in an upper middle to high
socioeconomic population in Chile [42].
Several strengths and caveats of our study are worth
noting. We used data on ILI and laboratory-confirmed
influenza cases reported to the IMSS, where about one-
third of all ILI cases were consistently tested for influ-
enza in all regions and throughout the main pandemic
period [7]. We compared the case fatality ratio across
regions, pandemic waves, age groups, and patterns of
neuraminidase inhibitor administration in Mexico. Of
note, there was no evidence of weaker disease surveil-
lance in smaller states, and testing rates for novel A/
H1N1 influenza remained stable throughout the pan-
demic period [7]. Moreover, only a small fraction of the
records had missing data. Specifically, 0.2% of all records
missing the date of symptoms onset, 4% of inpatient
records missing admission delay, and antiviral treatment
was missing in 0.1% of records. We also note that the
exact timing of start of antiviral treatment was not avail-
able. Data on antiviral treatment was available for those
patients treated upon initial consultation or admission in
hospitals, but were not able to ascertain antiviral treatment
for patients well initially and therefore untreated, and dete-
riorated subsequently during hospitalization. The study
patients, who visited the IMSS facilities, were likely to be
representative of those patients with more severe disease,
given the representativeness of the IMSS system. We note
that antiviral treatment patterns among IMSS-affiliated
populations may have been slightly higher than among
non-IMSS populations, given the slightly higher socio-eco-
nomic status of IMSS affiliates. Further, due to lack of in-
formation on the sensitivity and specificity of the ILI and
ARI definitions used in the IMSS system [49], we consid-
ered both ILI/ARI and laboratory-confirmed outcomes in
our analyses.
Another limitation of our analysis of disease severity
was to disregard the impact of underlying chronic condi-
tions. Our study was focused on relative comparisons of
disease severity over time, geography, and treatment
groups, and we assumed similar underlying conditions in
comparison groups. Lastly, a subset of our A/H1N1-
positive patients may have had secondary bacterial infec-
tion, but no data was available to evaluate the role of
bacterial coinfections or antibiotic treatment on severity
of A/H1N1 infection [50,51].
Conclusions
We found an association between the case fatality ratio
of the 2009 A/H1N1 influenza pandemic in Mexico and
hospital admission delays, neuraminidase inhibitor treat-
ment, demographics, and geography. Our results suggest
that differences in antiviral treatment rates and admis-
sion delays could partly explain the reported variability
in pandemic mortality burden between high and middle-
income countries. Severity patterns in low-income
regions, especially in Africa, may differ from those
reported here and be related to frequency of underlying
chronic conditions or access to care. More information
on disease severity in low-income regions is warranted.
Overall, our study underscores the potential impact of
decreasing admission delays and increasing antiviral use
in the inpatient setting to mitigate the mortality burden
of future influenza pandemics.
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